PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis

Journal of Microencapsulation

Volumn 29, Issue 1, 2012, Pages 83-94

  Haeri, Azadeh ^a   Sadeghian, Saeed ^b   Rabbani, Shahram ^b   Anvari, Maryam Sotoudeh ^b   Erfan, Mohammad ^a   Dadashzadeh, Simin ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Estradiol benzoate; Liposomes; Local delivery; PEGylation; Restenosis; Sustained release

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; EGG PHOSPHATIDYLCHOLINE; ESTRADIOL BENZOATE; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FILM; HYDRATION; IN VIVO STUDY; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RAT; RESPONSE SURFACE METHOD; RESTENOSIS; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; BLOOD VESSELS; CORONARY STENOSIS; ESTRADIOL; HUMANS; LIPOSOMES; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84855894556     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.630107     Document Type: Article

References (53)

1. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev, 2006;58:387-401. (Pubitemid 43816741)
2. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim Biophys Acta, 1991;1068:133-41.
3. Armstrong NA, 2006. Pharmaceutical experimental design and interpretation. New York: Taylor & Francis Group.
4. Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, Lazarovichi G, Gazit A, Levitzki A, Golomb G. Locally delivered nanoencapsulated tyr-phostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials, 2005;26:451-61. (Pubitemid 38951112)
5. Betageri GV, Parsons DL. Drug encapsulation and release from multilamel-lar and unilamellar liposomes. Int J Pharm, 1992;81:235-41.
6. Brito L, Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine, 2007;2:143-61. (Pubitemid 47215016)
7. Burt HM, Hunter WL. Drug-eluting stents: An innovative multidisciplinary drug delivery platform. Adv Drug Deliv Rev, 2006;58:345-6. (Pubitemid 43816736)
8. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation, 2005;111:2257-73. (Pubitemid 40632443)
9. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta, 2007;1768:1367-77. (Pubitemid 46782695)
10. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta, 2002;1561:188-201. (Pubitemid 34454786)
11. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 1999;51:691-743.
12. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocar-rier development. J Pharm Sci, 2008;97:4696-740.
13. Foegh ML, Asotra S, Howell MH, Ramwell PW. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg, 1994;19: 722-6. (Pubitemid 24137129)
14. Genereux P, Mehran R. Are drug-eluting stents safe in the long term?. CMAJ, 2009;180:154-5.
15. Hanke H, Hassenstein S, Ulmer A, Kamenz J, Oberhoff M, Haase KK, Baumbach A, Gown AM, Karsch KR. Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. Eur Heart J, 1994;15:691-8. (Pubitemid 24186339)
16. Herrington D. Role of estrogens, selective estrogen receptor modulators and phytoestrogens in cardiovascular protection. Can J Cardiol, 2000;16 Suppl E:5E-9E.
17. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release, 2003;91:417-29. (Pubitemid 36980659)
18. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine, 2006;1:297-315.
19. Kedia G, Lee MS. Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheter Cardiovasc Interv, 2007;69:782-9. (Pubitemid 46867477)
20. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J, 1980;186:591-8.
21. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histolo-gical, and immunohistochemical analyses. Circulation, 1998;98:224-33. (Pubitemid 28337613)
22. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy R. Arterial uptake of biodegradable nanoparticles: Effect of surface modifications. J Pharm Sci, 1998;87:1229-34. (Pubitemid 28455614)
23. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol, 1997;273:L119-26.
24. Lee MS, David EM, Makkar RR, Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: The intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. J Pathol, 2004;203:861-70. (Pubitemid 39089273)
25. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation, 2007;115:1051-8. (Pubitemid 46328299)
26. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of anti-platelet therapy. Lancet, 2004;364:1519-21. (Pubitemid 39410418)
27. Melikian N, Airoldi F, Di Mario C. Coronary bifurcation stenting. Current techniques, outcome and possible future developments. Minerva Cardioangiol, 2004;52:365-78. (Pubitemid 39457518)
28. Melikian N, Wijns W. Drug-eluting stents: A critique. Heart, 2008;94:145-52. (Pubitemid 351211718)
29. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation, 1996;94:3098-102. (Pubitemid 26427473)
30. Moribe K, Maruyama K, Iwatsuru M. Encapsulation characteristics of nys-tatin in liposomes: Effects of cholesterol and polyethylene glycol derivatives. Int J Pharm, 1999;188:193-202. (Pubitemid 29486722)
31. Nallamothu R, Wood GC, Kiani MF, Moore BM, Horton FP, Thoma LA. A targeted liposome delivery system for combretastatin A4: Formulation optimization through drug loading and in vitro release studies. PDA J Pharm Sci Technol, 2006;60:144-55. (Pubitemid 43974711)
32. New G, Moses JW, Roubin GS, Leon MB, Colombo A, Iyer SS, Tio FO, Mehran R, Kipshidze N. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv, 2002;57:266-71.
33. Ogihara-Umeda I, Kojima S. Cholesterol enhances the delivery of lipo-some-encapsulated gallium-67 to tumors. Eur J Nucl Med, 1989;15: 612-17. (Pubitemid 19236005)
34. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 2005;45:2088-92. (Pubitemid 40814135)
35. Oparil S, Chen SJ, Chen YF, Durand JN, Allen L, Thompson JA. Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Cardiovasc Res, 1999;44:608-14. (Pubitemid 30012065)
36. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation, 1991;84:1426-36.
37. Ramana LN, Sethuraman S, Ranga U, Krishnan UM. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci, 2010;17:57.
38. Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release, 1987;5:23-36. (Pubitemid 17106643)
39. Salam AM, Al Suwaidi J, Holmes DR. Drug-eluting coronary stents. Curr Probl Cardiol, 2006;31:8-119. (Pubitemid 43017767)
40. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation, 2004;110:810-14. (Pubitemid 39096008)
41. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry, 1996;35:2521-5. (Pubitemid 26098761)
42. Silbiger S, Lei J, Ziyadeh FN, Neugarten J. Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol, 1998;274:F1113-18.
43. Steffel J, Tanner FC. Biological effects of drug-eluting stents in the coronary circulation. Herz, 2007;32:268-73. (Pubitemid 47047280)
44. Sukhija R, Mehta JL, Sachdeva R. Present status of coronary bifurcation stenting. Clin Cardiol, 2008;31:63-6. (Pubitemid 351317214)
45. Sullivan TR, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF, Mendelsohn ME. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest, 1995;96:2482-8.
46. Tsotas VA, Mourtas S, Antimisiaris SG. Dexamethasone incorporating liposomes: Effect of lipid composition on drug trapping efficiency and vesicle stability. Drug Deliv, 2007;14:441-5. (Pubitemid 350125733)
47. Tulis DA. Rat carotid artery balloon injury model. Methods Mol Med, 2007;139:1-30.
48. Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm, 2008;34:10-23. (Pubitemid 351156969)
49. White CR, Shelton J, Chen SJ, Darley-Usmar V, Allen L, Nabors C, Sanders PW, Chen YF, Oparil S. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation, 1997;96:1624-30. (Pubitemid 27375362)
50. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta, 1992;1113:171-99.
51. Xiong Y, Guo D, Wang L, Zheng X, Zhang Y, Chen J. Development of nobiliside A loaded liposomal formulation using response surface methodology. Int J Pharm, 2009;371:197-203.
52. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterization of a novel Cremophor EL free lipo-some-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm, 2005;59:177-87. (Pubitemid 39573451)
53. Zuidam JZ, de Vrueh R, Crommelin DJA, 2003. Characterization of liposomes. In: Torchilin VP, Weissig V, eds. Liposomes: A practical approach. New York: Oxford University Press. pp. 31-78.